Table 1

Characteristics of tegaserod initiators and comparators at baseline1
Characteristic or Condition Tegaserod initiators (N = 2,762) Comparison cohort (N = 2,762)
N % N %
Age group
 0-29 386 14.0% 386 14.0%
 30-49 1,416 51.3% 1,412 51.1%
 50+ 960 34.8% 964 34.9%
Sex
 Female 2,496 90.4% 2,435 88.2%
Region
 Northeast 73 2.6% 70 2.5%
 South & Southeast 1,256 45.5% 1,312 47.5%
 Midwest 1,228 44.5% 1,159 42.0%
 West 205 7.4% 221 8.0%
Select Baseline Diagnoses
 Abdomen / Pelvis Symptoms (ICD-9 789) 1,413 51.2% 1,417 51.3%
 Irritable Bowel Syndrome (ICD-9 564.1) 1,150 41.6% 1,117 40.4%
 Constipation (ICD-9 564.0) 1,027 37.2% 967 35.0%
 GI System Symptoms (ICD-9 787) 886 32.1% 1,050 38.0%
Select Baseline Procedures
 Surgical Pathology (CPT 88305) 696 25.2% 700 25.3%
 Colon Procedures (CPT 643 23.3% 665 24.1%
 CT Scan Abdomen (CPT 74150–74175) 413 15.0% 426 15.4%
 Abdominal Ultrasound (CPT 381 13.8% 401 14.5%
 Gallbladder Radiography (CPT 84 3.0% 66 2.4%
 Gallbladder Surgery (CPT 46 1.7% 42 1.5%
Baseline Drug Classes Dispensed
 Proton Pump Inhibitors 1,029 37.3% 1,059 38.3%
 Analgesics, Narcotics 955 34.6% 998 36.1%
 Serotonin Specific Reuptake Inhibitor 692 25.1% 686 24.8%
 Laxative Drugs 533 19.3% 522 18.9%
Baseline Healthcare Utilization Mean Median Mean Median
 Total Cost ($) 4,319.40 2,127.77 4,750.59 2,254.55
 Physician Costs (US$) 1,501.48 828.12 1,576.03 849.34
 Cost of Pharmaceuticals (US$) 923.33 461.04 937.55 405.71
 Gastroenterologist Visits 1.6 1 1.6 0
 Number of Drug Classes Dispensed 7.9 7 7.8 7

1 Defined as the six-month period preceding start of follow-up.

Seeger et al.

Seeger et al. BMC Gastroenterology 2012 12:171   doi:10.1186/1471-230X-12-171

Open Data